Semiannual Report — FY2026 H1
What Eisai Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-12View the original on EDINET
How much it says
58Typical
What moved here
17named for the first time
Its own wording
28terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim period from 1 April 2026 to 30 September 2026, revenue, operating profit and interim profit all increased, with growth in LENVIMA, LEQEMBI and DAYVIGO cited as the main drivers. The company also launched LEQEMBI IQLIK, a subcutaneous autoinjector formulation of LEQEMBI, as an initial therapy in the United States, and disclosed new launches of LEQEMBI in other regions.
Komori's summary of this document, not the document's own words.58Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
49
Typical
62
Detailed
25
Almost nothing
68
Detailed
71
Detailed
48
Typical
60
Detailed
55
Typical
50
Typical
R&D spend881億円Money spent making new things.
Cash left over329億円Cash from the business, less what went into equipment.
Spent on equipment100億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.